{"effect":{"id":"hair_loss","name":"Hair loss (thinning)","severity":"mild","description":"Noticeable hair thinning or shedding. The FDA Wegovy prescribing information (revised 06/2026) describes hair-loss adverse reactions as associated with weight reduction and reported more often in women (4% vs 0.9% of men on 2.4 mg); it attributes no further mechanism.","clinicalRates":{"low":0.03,"medium":0.03,"high":0.03},"clinicalRatesNote":"A fixed reference table dated 2026-04-12, not derived from this corpus and carrying no per-effect citation of its own — see `sources` on ?q=effect&id=<id> for what was recorded behind each effect. It reaches published numbers two ways. (1) As the sole clinical base for an effect with no eligible corpus rate point — exactly the effects whose pooled corpus estimate is null (corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint); the predictor marks these isFallback: true. (2) Since 2026-08-28, as a dose-tier rescale ratio applied to the corpus's OWN pooled rate wherever that tier's pooled clinical records are mostly dose-untagged; isFallback stays false in that case, and the predictor's clinical.basis states both endpoints and the dose-tag denominator while clinical.pooledPercentage carries the corpus rate before any adjustment. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>. WITHDRAWN 2026-09-03 (decision literature-fallback-clinical-rate-2026-08-28, option c) for emotional_blunting only: this table had no rate-stating source at all for it, so its clinicalRate fields are null here and its predictor track carries `available: false` with no percentage — see clinicalRatesWithdrawn on ?q=effect&id=emotional_blunting. RE-SOURCED 2026-09-03 (same decision, option b) for fatigue only: its three tier values are one figure, 0.11, from the FDA Wegovy prescribing information revised 06/2026 (Table 3: fatigue incl. asthenia 11% on 2.4 mg, N=2,116, vs 5% placebo, N=1,261; URL in its sources) — the label reports no per-dose-tier rate, so no gradient is published for it, and it is a semaglutide figure applied at every dose tier regardless of molecule, as this whole table is. RE-SOURCED 2026-09-04 (decision pancreatitis-hairloss-dizziness-triple-derivation-2026-09-03) for hair_loss, dizziness and pancreatitis: their 2026-04-12 triples (1–3%, 2–5%, 0.5–1.2%) had no recorded derivation and their cited trial pages state no such figures; each is now one value at every tier from the same FDA Wegovy label — hair_loss 0.03 (Table 3: 3% on 2.4 mg, N=2,116, vs 1% placebo), dizziness 0.08 (Table 3: 8% vs 4%), and pancreatitis 0.002, which is NOT a proportion of patients like every other value in this table but the label's incidence RATE of 0.2 acute-pancreatitis cases per 100 patient-years of Wegovy exposure (4 adjudicated cases vs 1 on placebo, section 5) — read it with that unit. Figures served before 2026-09-04 for these three effects should not be cited.","confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","modifiers":{"femaleFactor":1.4,"ageFactor65plus":1.2,"giHistoryFactor":1,"diabetesFactor":1,"firstMonthFactor":0.3},"modifiersNote":"Odds ratios hand-coded at the 2026-04-12 seed with no per-modifier citation recorded — treat each as an expert-coded prior, not a sourced estimate. The FDR-corrected empirical estimator runs daily but no effect yet meets its evidence bar (model config v1, zero empirical modifiers applied). See ?q=help for the full methodology note.","reportingFrequency":{"mentions":1,"distinctReports":26,"sharePct":3.8,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."},"userReportedSeverity":"Community reports describe increased shedding starting around month 3-4, often alongside rapid weight loss. Most who report it say it stabilises once weight loss plateaus; some describe it easing sooner with adequate dietary protein and iron intake.","onsetDays":"Typically 2-4 months after starting (delayed onset)","durationWeeks":"Usually temporary — 3-6 months, then regrowth","managementTip":"Ensure adequate protein intake (60-80g/day), consider a multivitamin with biotin, iron, and zinc. Hair loss from weight loss is almost always temporary.","sources":[{"name":"FDA Wegovy (semaglutide) prescribing information, revised 06/2026, Table 3: hair loss 3% on 2.4 mg (N=2,116) vs 1% placebo (N=1,261); Table 4 (7.2 mg trial): 1% / 3% / 6% for placebo / 2.4 mg / 7.2 mg","type":"clinical","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","weight":0.3},{"name":"Reddit r/Ozempic hair loss megathread (2024-2026)","type":"user_report","weight":0.4},{"name":"RAND Corporation side effects study (2025)","type":"news","url":"https://www.rand.org/pubs/research_reports/RRA4153-1.html","weight":0.3}]},"dataPointCount":36,"rateBase":{"note":"Only externally citable, non-duplicated rates support an estimate. Shares of spontaneous adverse-event reports (FAERS) are reported separately — they are not incidence.","clinical":{"statedRates":0,"distinctSources":0,"pooledEstimate":null,"confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","sources":[],"excluded":{"seed_unverified":3,"no_rate":8},"usesPublishedFallback":true},"community":{"statedRates":0,"distinctSources":0,"excluded":{"no_rate":16,"seed_unverified":7,"aggregator_result":2},"usesPublishedFallback":true},"spontaneousReportShares":[]},"dataPointsBySource":{"clinical":11,"regulatory":0,"user_report":14,"news":11},"sampleDataPoints":[{"sourceName":"Reddit r/mentalhealth — I'm so tired of fighting with my brain","sourceType":"user_report","sourceUrl":"https://reddit.com/r/mentalhealth/comments/1sfgz3l/im_so_tired_of_fighting_with_my_brain/","extractedRate":null,"extractedSeverity":null,"extractedSampleSize":null,"extractionConfidence":"low","scrapedAt":"2026-04-08T04:02:18.751Z","excludedFromPublished":"off-topic source: not a GLP-1/weight-management/diabetes community report"},{"sourceName":"Reddit r/FemaleHairLoss — Medication and supplement recs if minoxidil didn't work for you?","sourceType":"user_report","sourceUrl":"https://reddit.com/r/FemaleHairLoss/comments/1sfh5qh/medication_and_supplement_recs_if_minoxidil_didnt/","extractedRate":null,"extractedSeverity":null,"extractedSampleSize":null,"extractionConfidence":"high","scrapedAt":"2026-04-08T04:02:25.305Z","excludedFromPublished":"off-topic source: not a GLP-1/weight-management/diabetes community report"},{"sourceName":"SELECT Trial (Lincoff et al., NEJM 2023)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2307563","extractedRate":0.01,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-12T12:37:28.021Z"},{"sourceName":"SELECT Trial (Lincoff et al., NEJM 2023)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2307563","extractedRate":0.02,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-12T12:37:28.021Z"},{"sourceName":"SELECT Trial (Lincoff et al., NEJM 2023)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2307563","extractedRate":0.03,"extractedSeverity":"mild","extractedSampleSize":300,"extractionConfidence":"high","scrapedAt":"2026-04-12T12:37:28.021Z"}],"lastUpdated":"2026-08-22"}